Home Companies Catalysts Deep Dives
Yeztugo lenacapavir APPROVED
Drug Profile
ModalitySmall molecule
RouteSC
Therapy AreaInfectious Disease
Launch2025-06-20
US LOE2037-06-20
Peak Sales Est$5000M
Formulations[{"id":"yeztugo-sc","route":"SC","setting":"HCP_ADMINISTERED","frequency":"Twice yearly","is_primary
Companies
GILD (ORIGINATOR)100%
Mechanism: Capsid inhibitor
Expert: First-in-class HIV-1 capsid inhibitor interfering with multiple stages of viral replication.
Everyday: Disrupts the protective shell of HIV, preventing it from replicating.
Targets: ["HBV CAPSID"]
Revenue History
PeriodRevenue ($M)
Q3 2025$27M
Q4 2025$96M
2025$150M
Programs (1)
IndicationStageKey StudyRegional Status
HIV-1 PrEPAPPROVEDPURPOSE-1/PURPOSE-2[{"stage":"APPROVED","region":"US","approval_date":"2025-06-20"}]
Data from Supabase · Updated 2026-03-24